Syndeio Biosciences (from the Ancient Greek word “to connect”) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company’s proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Syndeio’s clinical pipeline includes lead asset, zelquistinel, currently in Phase 2 development for major depressive disorder and will soon be entering an industry-first biomarker study in Alzheimer’s disease, and apimostinel, currently in an investigator-led phase 2 study for acute depression. The company is headquartered in Indianapolis, IN with research laboratories in Menlo Park, CA & Evanston, IL focused on advancing the Boost™ Synapse Pharmacology Platform.
Company Details
- Employees
- 22
- Founded
- 2025
- Address
- Indianapolis, In, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.syndeio.bio
- HQ
- Indianapolis, IN
Syndeio Biosciences Questions
Syndeio Biosciences's website is http://www.syndeio.bio
Syndeio Biosciences's LinkedIn profile is https://www.linkedin.com/company/syndeio-biosciences
Syndeio Biosciences has
22 employees.
View email and phone details for 22
employees at Syndeio Biosciences.
Syndeio Biosciences's industry is
Biotechnology Research
Syndeio Biosciences's top competitors are
Haya Therapeutics,
Azafaros B.v.,
Ausperbio,
Newlimit,
Juvenescence®,
Grin Therapeutics, Inc.,
Cellcentric,
Stylus Medicine,
Repronovo,
Syndeio Bio.
Syndeio Biosciences's categories are Biotechnology Research
Syndeio Biosciences's founding year is 2025
